上皮性卵巢癌(EOC)是女性中第八大最常见的癌症，大多数患者被诊断为晚期，尽管对一线治疗（通常是细胞减灭术联合铂类化疗）的初始反应很高，但晚期卵巢癌患者的总体5年生存率仍然很低，仅为29%3。

Epithelial ovarian cancer (EOC) is the eighth most common cancer in women. Most patients are diagnosed with advanced ovarian cancer. Despite a high initial response to first-line therapy, usually cytolytic therapy combined with platinum-based chemotherapy, the overall 5-year survival rate for patients with advanced ovarian cancer remains low at 29%3.

芦卡帕尼

　　Rucaparib芦卡帕尼（以前称为CO-338、AG-014447和PF-01367338）是一种设计合理、口服给药的PARP1、PARP2和PARP3小分子抑制剂。芦卡帕尼的推荐剂量和时间表是600毫克（两片300毫克片剂），每天口服两次(BID)。

　　不过芦卡帕尼可以根据患者的实际情况进行给药治疗，芦卡帕尼现在也已经在印度成功上市，在印度代购有详细药品介绍。

However, rucapanil can be administered according to the actual situation of the patient. Rucapanil has been successfully marketed in India, and there is a detailed introduction of the drug in India.